Blockade of preS2 down-regulates the apoptosis of HepG2.2.15 cells induced by TRAIL

Biochemical and Biophysical Research Communications

Volumn 369, Issue 2, 2008, Pages 456-463

  Liang, Xiaohong ^a   Qu, Zhonghua ^a   Zhang, Zhiyong ^a   Du, Juan ^a   Liu, Yugang ^a   Cui, Min ^a   Liu, Hua ^a   Gao, Lifen ^a   Han, Lihui ^a   Liu, Suxia ^a   Cao, Lili ^b   Zhao, Peiqing ^a   Sun, Wensheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Hepatitis B virus; PreS2 domain; TRAIL

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; PROTEIN PRES2; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; VIRUS PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER CELL; PRIORITY JOURNAL; VIRUS GENOME;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HEPATITIS B SURFACE ANTIGENS; HUMANS; PROTEIN PRECURSORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

HEPATITIS B VIRUS;

EID: 40849104741     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.02.035     Document Type: Article

References (27)

1. Liu D.X. A new hypothesis of pathogenetic mechanism of viral hepatitis B and C. Med. Hypotheses 56 (2001) 405-408
2. Zheng S., Wang P., Tsabary G., and Chen Y.H. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113 (2004) 58-64
3. Ksontini R., Colagiovanni D.B., Josephs M.D., Edwards C.K., Tannahill C.L., Solorzano C.C., Norman J., Denham W., Clare-Salzler M., MacKay S.L., and Moldawer L.L. Disparate roles for TNFalpha and Fas ligand in concanavalin A-induced hepatitis. J. Immunol. 160 (1998) 4082-4089
4. Kondo T., Suda T., Fukuyama H., Adachi M., and Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat. Med. 3 (1997) 409-413
5. Wiley S.R., Schooley K., Smolak P.J., Din W.S., Huang C.P., Nicholl J.K., Sutherland G.R., Smith T.D., Rauch C., and Smith C.A. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
6. Schneider P., Thome M., Burns K., Bodmer J.-L., Hofmann K., Kataoka T., Holler N., and Tschopp J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kappaB. Immunity 7 (1997) 831-836
7. Pan G., Ni J., Wei Y.F., Yu G., Gentz R., and Dixit V.M. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 277 (1997) 815-818
8. Clarke P., Meintzer S.M., Spalding A.C., Johnson G.L., and Tyler K.L. Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 20 (2001) 6910-6919
9. Mundt B., Kuhnel F., Zender L., Paul Y., Tillmann H., Trautwein C., Manns M.P., and Kubicka S. Involvement of TRAIL and its receptors in viral hepatitis. FASEB J. 17 (2003) 94-96
10. Zheng S., Wang P., Tsabary G., and Chen Y.H. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J. Clin. Invest. 113 (2004) 58-64
11. Liang X.H., Liu Y.G., Zhang Q., Gao L., Han L., Ma C., Zhang L., Chen Y.H., and Sun W. Hepatitis B virus sensitizes hepatocytes to TRAIL-induced apoptosis through Bax. J. Immunol. 178 (2007) 503-510
12. Liang X.H., Sun W.S., Gao L.F., Ma C.H., Han L.H., and Chen Y.H. Hepatitis B virus X protein modulates the apoptosis of hepatoma cell line induced by TRAIL. Sci. China (Engl. version) 4 (2005) 277-286
13. Liu Y.G., Liu S.X., Liang X.H., Zhang Q., Gao L.F., Han L.H., Cao Y.L., Hou N., Du J., and Sun W.S. Blockade of TRAIL pathway ameliorates HBV-induced hepatocyte apoptosis in an acute hepatitis model. Biochem. Biophys. Res. Commun. 352 (2007) 329-334
14. Machida A., Kishimoto S., Ohnuma H., Moyamoto H., Baba K., Oda K., Nakamura T., Miyakawa Y., and Mayumi M.A. Hepatitis B surface antigen polypeptide (p31) with the receptor for polymerized human as well as chimpanzee albumins. Gastroenterology 85 (1983) 268-274
15. Sobotta D., Sominskaya I., Jansons J., Meisel H., Schmitt S., Heermann K.H., Kaluza G., Pumpens P., and Gerlich W.H. Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J. Gen. Virol. 81 (2000) 369-378
16. Cho E.W., Park J.H., Yoo O.J., and Kim K.L. Translocation and accumulation of exogeneous hepatitis B virus preS surface proteins in the cell nucleus. J. Cell Sci. 114 (2001) 1115-1123
17. Bruss V., Lu R., Thomssen R., and Gerlich W. Post translational alterations in the transmembrane topology of the hepatitis B virus large envelope protein. EMBO J. 13 (1994) 2273-2279
18. Hildt E., Urban S., and Hofschneider P.H. Characterization of essential domains for the functionality of the MHBst transcriptional activator and identification of a minimal MHBst activator. Oncogene 11 (1995) 2055-2066
19. Hildt E., Munz B., Saher G., Reifenberg K., and Hofschneider P.H. The PreS2 activator MHBs(t) of hepatitis B virus activates c-raf-1/Erk2 signaling in transgenic mice. EMBO J. 15 (2002) 525-535
20. Hildt E., and Hofschneider P.H. The PreS2 activators of the hepatitis B virus: activators of tumour promoter pathways. Recent Results Cancer Res. 154 (1998) 315-329
21. Shin E.C., Seong Y.R., Kim C.H., Kim H., Ahn Y.S., Kim K., Kim S.J., Hong S.S., and Park J.H. Human hepatocellular carcinoma cells resist to TRAIL-induced apoptosis, and the resistance is abolished by cisplatin. Exp. Mol. Med. 34 (2002) 114-122
22. Kabsch K., and Alonso A. The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms. J. Virol. 76 (2002) 12162-12172
23. Walczak H., Miller R.E., Ariail K., Gliniak B., Griffith T.S., Kubin M., Chin W., Jones J., Woodward A., Le T., Smith C., Smolak P., Goodwin R.G., Rauch C.T., Schuh J.C., and Lynch D.H. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. 5 (1999) 157-163
24. Kagi D., Vignaus F., Ledermann B., Bürki K., Depraetere V., Nagata S., Hengartner H., and Golstein P. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265 (1994) 528-530
25. Evdokiou A., Bouralexis S., Atkins G.J., Chai F., Hay S., Clayer M., and Findlay D.M. Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to Apo2L/TRAIL-induced apoptosis. Int. J. Cancer 99 (2002) 491-504
26. Frese S., Pirnia F., Miescher D., Krajewski S., Borner M.M., Reed J.C., and Schmid R.A. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene 22 (2003) 5427-5435
27. Wang X., Martindale J.L., and Holbrook N.J. Requirement for ERK activation in cisplatin-induced apoptosis. J. Biol. Chem. 275 (2000) 39435-39443